Roche sues Cipla over cut-price version of Valcyte
This article was originally published in Scrip
Executive Summary
Roche has moved to the Bombay High Court against Cipla, over the latter's alleged infringement of its patent and trademark for Valcyte (valganciclovir). Roche's Valcyte is used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.